NCT05377307 - Long-term Follow-up Study of Lentiviral-based Gene-edited Immune Cell Therapy | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 29, 2022

Primary Completion Date

December 31, 2036

Study Completion Date

December 31, 2037

Conditions

Diffuse Large B Cell LymphomaLarge B-cell LymphomaPrimary Mediastinal Large B Cell LymphomaFollicular Lymphoma Grade 3AFollicular Lymphoma Grade 3B

Interventions

GENETIC

Pell's lentiviral-based gene-edited immune cell therapy

No study drug or other planned treatment will be administered. Subjects who previously received Pell's lentiviral-based gene-edited immune cell therapy will be evaluated the safety and efficacy.

Trial Locations (5)

710

RECRUITING

Chi Mei Medical Center, Tainan City

10025

RECRUITING

National Taiwan University Hospital, Taipei

11031

RECRUITING

Taipei Medical University - Taipei Medical University Hospital, Taipei

112201

RECRUITING

Taipei Veterans General Hospital, Taipei

807377

RECRUITING

Kaohsiung Medical University Chung-Ho Memorial Hospital, Kaohsiung

All Listed Sponsors

lead

Pell Bio-Med Technology Co., Ltd.

INDUSTRY